|No phase specified||Treatment||Completed||18 and over||Other||1056757|
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Further Study Information
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine
Trial Lead Organizations/Sponsors
Kentuckiana Cancer Institute, PLLC
|Renato Vincenzo LaRocca||Study Director|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00283478
Information obtained from ClinicalTrials.gov on November 20, 2012
Back to Top